跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT01380093
NCT01380093已完成1 期

A Randomized, Double-Blind, Placebo- and Active-Controlled, 3-Way Crossover Study to Determine the Abuse Potential of Oral Administration of Crushed EMBEDA Relative to Crushed Controlled-Release Morphine Sulfate and Placebo in Non Dependent, Recreational Opioid Users

Pfizer1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2011年2月最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Pfizer
入组人数
80
试验地点
1
主要终点
Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The primary purpose of this study is to determine the abuse potential of EMBEDA compared to controlled release morphine when crushed and taken orally by non-dependent recreational opioid users; secondary purposes include to determine the abuse potential of crushed EMBEDA relative to placebo and and to compare the pharmacokinetics and safety of crushed EMBEDA with crushed controlled-release morphine and crushed placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 55 Years（Adult）
性别
All
接受健康志愿者
是

入选标准

  • •Subject is a recreational opioid user who is NOT physically dependent on opioids based on Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR) criteria, and the Naloxone Challenge. A recreational opioid user is defined as recreationally abusing opioids for non-therapeutic purposes (i.e., for psychoactive effects) on at least 10 occasions within the last year and at least once in the 12 weeks prior to Visit
  • •Subject is in generally good health as determined by medical history, physical examination, vital signs, clinical laboratory tests, and 12-lead electrocardiogram (ECG).

排除标准

  • •Has a history or current diagnosis of substance dependence (excluding caffeine and nicotine), as assessed by the Investigator using the DSM IV-TR criteria.
  • •Has participated in, is currently participating in, or is seeking treatment for substance- and/or alcohol-related disorders (excluding nicotine and caffeine).
  • •History or presence of any clinically significant illness (e.g., cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, musculoskeletal, or psychiatric) or any other condition, which in the opinion of the Investigator would jeopardize the safety of the subject or the validity of the study results.
  • •Has a known allergy or history of hypersensitivity to morphine sulfate, opioids in general, naltrexone hydrochloride (HCl) or similar compounds and/or the known excipients in the investigational drug products.
  • •Has any condition in which an opioid is contraindicated (e.g., significant respiratory depression, acute or severe bronchial asthma or hypercarbia, or is suspected of having paralytic ileus).
  • •Females who are pregnant, lactating, or are planning to become pregnant during the course of the study. Females with a positive serum pregnancy test at Visit 1 or at any subsequent study visit will be excluded from participating in the study.

研究组 & 干预措施

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

MS Contin (morphine sulfate, controlled release)

Active Comparator

干预措施: MS Contin (morphine sulfate, controlled release) (Drug)

EMBEDA (morphine sulfate / naltrexone hydrochloride)

Experimental

干预措施: EMBEDA (morphine sulfate / naltrexone hydrochloride) (Drug)

结局指标

主要结局

Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours

时间窗: 0.5, 1, 1.5 and 2 hrs post-dose

Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of "neither like nor dislike" (score of 50 mm), on the left with "strong disliking" (score of 0 mm) and on the right with "strong liking" (score of 100 mm). AUE (0-2) = Area under the effect versus time curve from time 0 to 2 hours (hrs) (0-2).

Drug Liking: Peak Effect (Emax)

时间窗: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose

Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of "neither like nor dislike" (score of 50 mm), on the left with "strong disliking" (score of 0 mm) and on the right with "strong liking" (score of 100 mm). Emax = Maximum observed score.

High: Area Under Effect Curve (AUE) From 0-2 Hours

时间窗: 0.5, 1, 1.5 and 2 hrs post-dose

High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-2) = Area under the effect versus time curve from time 0 to 2 hrs (0-2).

High: Peak Effect (Emax)

时间窗: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose

High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.

次要结局

  • Good Effects: Area Under Effect Curve (AUE) From 0-4 Hours(0.5, 1, 1.5, 2, 3 and 4 hrs post-dose)
  • Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour(0.5 and 1 hrs post-dose)
  • Drug Liking: Area Under Effect Curve (AUE) From 0-4 Hours(0.5, 1, 1.5, 2, 3 and 4 hrs post-dose)
  • Drug Liking: Area Under Effect Curve (AUE) From 0-8 Hours(0.5, 1, 1.5, 2, 3, 4, 6 and 8 hrs post-dose)
  • Drug Liking: Area Under Effect Curve (AUE) From 0-12 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hrs post-dose)
  • Drug Liking: Area Under Effect Curve (AUE) From 0-24 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Drug Liking: Time to Maximum (Peak) Effect (TEmax)(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • High: Area Under Effect Curve (AUE) From 0-1 Hour(0.5 and 1 hrs post-dose)
  • High: Area Under Effect Curve (AUE) From 0-4 Hours(0.5, 1, 1.5, 2, 3 and 4 hrs post-dose)
  • High: Area Under Effect Curve (AUE) From 0-8 Hours(0.5, 1, 1.5, 2, 3, 4, 6 and 8 hrs post-dose)
  • High: Area Under Effect Curve (AUE) From 0-12 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hrs post-dose)
  • High: Area Under Effect Curve (AUE) From 0-24 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • High: Time to Maximum (Peak) Effect (TEmax)(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Good Effects: Area Under Effect Curve (AUE) From 0-1 Hour(0.5 and 1 hrs post-dose)
  • Good Effects: Area Under Effect Curve (AUE) From 0-2 Hours(0.5, 1, 1.5 and 2 hrs post-dose)
  • Good Effects: Area Under Effect Curve (AUE) From 0-8 Hours(0.5, 1, 1.5, 2, 3, 4, 6 and 8 hrs post-dose)
  • Good Effects: Area Under Effect Curve (AUE) From 0-12 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hrs post-dose)
  • Good Effects: Area Under Effect Curve (AUE) From 0-24 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Good Effects: Peak Effect (Emax)(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Good Effects: Time to Maximum (Peak) Effect (TEmax)(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Any Effects: Area Under Effect Curve (AUE) From 0-1 Hour(0.5 and 1 hrs post-dose)
  • Any Effects: Area Under Effect Curve (AUE) From 0-2 Hours(0.5, 1, 1.5 and 2 hrs post-dose)
  • Any Effects: Area Under Effect Curve (AUE) From 0-4 Hours(0.5, 1, 1.5, 2, 3 and 4 hrs post-dose)
  • Any Effects: Area Under Effect Curve (AUE) From 0-8 Hours(0.5, 1, 1.5, 2, 3, 4, 6 and 8 hrs post-dose)
  • Any Effects: Area Under Effect Curve (AUE) From 0-12 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hrs post-dose)
  • Any Effects: Area Under Effect Curve (AUE) From 0-24 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Any Effects: Peak Effect (Emax)(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Any Effects: Time to Maximum (Peak) Effect (TEmax)(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Bad Effects: Area Under Effect Curve (AUE) From 0-1 Hour(0.5 and 1 hrs post-dose)
  • Bad Effects: Area Under Effect Curve (AUE) From 0-2 Hours(0.5, 1, 1.5 and 2 hrs post-dose)
  • Bad Effects: Area Under Effect Curve (AUE) From 0-4 Hours(0.5, 1, 1.5, 2, 3 and 4 hrs post-dose)
  • Bad Effects: Area Under Effect Curve (AUE) From 0-8 Hours(0.5, 1, 1.5, 2, 3, 4, 6 and 8 hrs post-dose)
  • Bad Effects: Area Under Effect Curve (AUE) From 0-12 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hrs post-dose)
  • Bad Effects: Area Under Effect Curve (AUE) From 0-24 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Bad Effects: Peak Effect (Emax)(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Bad Effects: Time to Maximum (Peak) Effect (TEmax)(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Nausea: Area Under Effect Curve (AUE) From 0-1 Hour(Pre-dose, 0.5 and 1 hrs post-dose)
  • Nausea: Area Under Effect Curve (AUE) From 0-2 Hours(Pre-dose, 0.5, 1, 1.5 and 2 hrs post-dose)
  • Nausea: Area Under Effect Curve (AUE) From 0-4 Hours(Pre-dose, 0.5, 1, 1.5, 2, 3 and 4 hrs post-dose)
  • Nausea: Area Under Effect Curve (AUE) From 0-8 Hours(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6 and 8 hrs post-dose)
  • Nausea: Area Under Effect Curve (AUE) From 0-12 Hours(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hrs post-dose)
  • Nausea: Area Under Effect Curve (AUE) From 0-24 Hours(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Nausea: Peak Effect (Emax)(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Nausea: Time to Maximum (Peak) Effect (TEmax)(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Feel Sick: Area Under Effect Curve (AUE) From 0-1 Hour(0.5 and 1 hrs post-dose)
  • Feel Sick: Area Under Effect Curve (AUE) From 0-2 Hours(0.5, 1, 1.5 and 2 hrs post-dose)
  • Feel Sick: Area Under Effect Curve (AUE) From 0-4 Hours(0.5, 1, 1.5, 2, 3 and 4 hrs post-dose)
  • Feel Sick: Area Under Effect Curve (AUE) From 0-8 Hours(0.5, 1, 1.5, 2, 3, 4, 6 and 8 hrs post-dose)
  • Feel Sick: Area Under Effect Curve (AUE) From 0-12 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hrs post-dose)
  • Feel Sick: Area Under Effect Curve (AUE) From 0-24 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Feel Sick: Peak Effect (Emax)(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Feel Sick: Time to Maximum (Peak) Effect (TEmax)(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour(0.5 and 1 hrs post-dose)
  • Sleepy: Area Under Effect Curve (AUE) From 0-2 Hours(0.5, 1, 1.5 and 2 hrs post-dose)
  • Sleepy: Area Under Effect Curve (AUE) From 0-4 Hours(0.5, 1, 1.5, 2, 3 and 4 hrs post-dose)
  • Sleepy: Area Under Effect Curve (AUE) From 0-8 Hours(0.5, 1, 1.5, 2, 3, 4, 6 and 8 hrs post-dose)
  • Sleepy: Area Under Effect Curve (AUE) From 0-12 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hrs post-dose)
  • Sleepy: Area Under Effect Curve (AUE) From 0-24 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Sleepy: Peak Effect (Emax)(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Sleepy: Time to Maximum (Peak) Effect (TEmax)(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour(0.5 and 1 hrs post-dose)
  • Dizzy: Area Under Effect Curve (AUE) From 0-2 Hours(0.5, 1, 1.5 and 2 hrs post-dose)
  • Dizzy: Area Under Effect Curve (AUE) From 0-4 Hours(0.5, 1, 1.5, 2, 3 and 4 hrs post-dose)
  • Dizzy: Area Under Effect Curve (AUE) From 0-8 Hours(0.5, 1, 1.5, 2, 3, 4, 6 and 8 hrs post-dose)
  • Dizzy: Area Under Effect Curve (AUE) From 0-12 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hrs post-dose)
  • Dizzy: Area Under Effect Curve (AUE) From 0-24 Hours(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Dizzy: Peak Effect (Emax)(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Dizzy: Time to Maximum (Peak) Effect (TEmax)(0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Overall Drug Liking Effect at 24 Hours(24 hrs post dose)
  • Take Drug Again Effect at 24 Hours(24 hrs post dose)
  • Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour(Pre-dose, 0.5 and 1 hrs post-dose)
  • Pupillometry: Area Under Effect Curve (AUE) From 0-2 Hours(Pre-dose, 0.5, 1, 1.5 and 2 hrs post-dose)
  • Pupillometry: Area Under Effect Curve (AUE) From 0-4 Hours(Pre-dose, 0.5, 1, 1.5, 2, 3 and 4 hrs post-dose)
  • Pupillometry: Area Under Effect Curve (AUE) From 0-8 Hours(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6 and 8 hrs post-dose)
  • Pupillometry: Area Under Effect Curve (AUE) From 0-12 Hours(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hrs post-dose)
  • Pupillometry: Area Under Effect Curve (AUE) From 0-24 Hours(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Pupillometry: Peak Effect (Emax)(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Pupillometry: Time to Maximum (Peak) Effect (TEmax)(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Time to Reach Maximum Observed Plasma Concentration (Tmax) of Morphine(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Maximum Observed Plasma Concentration (Cmax) of Morphine(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-1)] of Morphine(Pre-dose, 0.5 and 1 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-2)] of Morphine(Pre-dose, 0.5, 1, 1.5 and 2 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-4)] of Morphine(Pre-dose, 0.5, 1, 1.5, 2, 3 and 4 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-8)] of Morphine(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6 and 8 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-12)] of Morphine(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Morphine(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Morphine(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Time to Reach Maximum Observed Plasma Concentration (Tmax) of Naltrexone(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Maximum Observed Plasma Concentration (Cmax) of Naltrexone(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-1)] of Naltrexone(Pre-dose, 0.5 and 1 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-2)] of Naltrexone(Pre-dose, 0.5, 1, 1.5 and 2 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-4)] of Naltrexone(Pre-dose, 0.5, 1, 1.5, 2, 3 and 4 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-8)] of Naltrexone(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6 and 8 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-12)] of Naltrexone(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Naltrexone(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Naltrexone(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Time to Reach Maximum Observed Plasma Concentration (Tmax) of Naltrexone Metabolite (6-beta-naltrexol)(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Maximum Observed Plasma Concentration (Cmax) of Naltrexone Metabolite (6-beta-naltrexol)(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-1)] of Naltrexone Metabolite (6-beta-naltrexol)(Pre-dose, 0.5 and 1 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-2)] of Naltrexone Metabolite (6-beta-naltrexol)(Pre-dose, 0.5, 1, 1.5 and 2 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-4)] of Naltrexone Metabolite (6-beta-naltrexol)(Pre-dose, 0.5, 1, 1.5, 2, 3 and 4 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-8)] of Naltrexone Metabolite (6-beta-naltrexol)(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6 and 8 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-12)] of Naltrexone Metabolite (6-beta-naltrexol)(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hrs post-dose)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Naltrexone Metabolite (6-beta-naltrexol)(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)
  • Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Naltrexone Metabolite (6-beta-naltrexol)(Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
1 期
A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant UsersHealthy VolunteersDrug Users
NCT02144415Otsuka Pharmaceutical Development & Commercialization, Inc.80
已完成
2 期
Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid UsersOpioid Abuse
NCT01030406Acura Pharmaceuticals Inc.49
已完成
1 期
EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal CancerMetastatic Colorectal Cancer
NCT01008475Merck KGaA, Darmstadt, Germany232
已完成
3 期
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or PlaceboCardiovascular DiseasesStatin Adverse Reaction
NCT02993406Esperion Therapeutics, Inc.13,970
已完成
2 期
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque PsoriasisModerate and Severe Plaque Psoriasis
NCT00885196Novartis Pharmaceuticals336
Abuse Potential of Orally Administered Crushed... | 临床试验